Good news for Novartis as GSK's Mekinist/Tafinlar trial stopped early
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's Phase III COMBI-v study of its MEK inhibitor, Mekinist (trametinib), in combination with its BRAF inhibitor, Tafinlar (dabrafenib), compared with Roche's Zelboraf (vemurafenib) in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic cutaneous melanoma has been stopped early.